Companion Animal Diagnostics Market Size, Share & Trends Analysis Report By Product (Consumables, Reagents & Kits, Equipment & Instruments), By Animal (Dogs, Cats, Horses), By Testing Category, By End Use, By Region, And Segment Forecasts, 2026 - 2033
Description
Companion Animal Diagnostics Market Summary
The global companion animal diagnostics market size was estimated at USD 7.06 billion in 2025 and is projected to reach USD 14.41 billion by 2033, growing at a CAGR of 9.27% from 2026 to 2033. The market is experiencing growth driven by rising pet ownership, increasing spending on advanced veterinary care, and growing awareness of early disease detection.
Key Market Trends & Insights
North America companion animal diagnostics market held the largest revenue share of 37.91% in 2025.The U.S. companion animal diagnostics market is dominated with the largest revenue share in 2025.By product, the consumables, reagents & kits segment held the largest share of 64.96% in the market in 2025By animal type, the dog segment is the largest in the market in 2025.Based on the testing category, the clinical chemistry segment held the largest market share in 2025.
Technological advancements such as point-of-care testing, molecular diagnostics, and AI-based imaging are further accelerating adoption across veterinary clinics worldwide. Moreover, in September 2024, Zoetis introduced the Vetscan OptiCell, an innovative, AI-powered, cartridge-based hematology analyzer designed to provide laboratory-grade complete blood count (CBC) results directly at the point of care. This next-generation diagnostic tool enhances clinical accuracy, streamline workflow efficiency, and features a compact, user-friendly design tailored for veterinary practices. The device is set to make its public debut at the London Vet Show in November 2024.
This cutting-edge innovation is poised to significantly drive growth in the companion animal diagnostics market. By enabling rapid, reliable, and on-site blood analysis, Vetscan OptiCell empowers veterinarians to make faster and more informed treatment decisions. The integration of AI not only boosts diagnostic precision but also reduces the need for outsourced lab services, thereby lowering turnaround time and operational costs. As veterinary clinics and hospitals increasingly seek advanced, easy-to-use diagnostic tools that deliver immediate results, demand for such point-of-care solutions is expected to rise, contributing to broader market expansion. Additionally, the launch strengthens Zoetis' leadership position in veterinary diagnostics, encouraging further innovation and investment in the sector.
Global Companion Animal Diagnostics Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the companion animal diagnostics market report based on product, animal, testing category, end use, and region.
The global companion animal diagnostics market size was estimated at USD 7.06 billion in 2025 and is projected to reach USD 14.41 billion by 2033, growing at a CAGR of 9.27% from 2026 to 2033. The market is experiencing growth driven by rising pet ownership, increasing spending on advanced veterinary care, and growing awareness of early disease detection.
Key Market Trends & Insights
North America companion animal diagnostics market held the largest revenue share of 37.91% in 2025.The U.S. companion animal diagnostics market is dominated with the largest revenue share in 2025.By product, the consumables, reagents & kits segment held the largest share of 64.96% in the market in 2025By animal type, the dog segment is the largest in the market in 2025.Based on the testing category, the clinical chemistry segment held the largest market share in 2025.
Technological advancements such as point-of-care testing, molecular diagnostics, and AI-based imaging are further accelerating adoption across veterinary clinics worldwide. Moreover, in September 2024, Zoetis introduced the Vetscan OptiCell, an innovative, AI-powered, cartridge-based hematology analyzer designed to provide laboratory-grade complete blood count (CBC) results directly at the point of care. This next-generation diagnostic tool enhances clinical accuracy, streamline workflow efficiency, and features a compact, user-friendly design tailored for veterinary practices. The device is set to make its public debut at the London Vet Show in November 2024.
This cutting-edge innovation is poised to significantly drive growth in the companion animal diagnostics market. By enabling rapid, reliable, and on-site blood analysis, Vetscan OptiCell empowers veterinarians to make faster and more informed treatment decisions. The integration of AI not only boosts diagnostic precision but also reduces the need for outsourced lab services, thereby lowering turnaround time and operational costs. As veterinary clinics and hospitals increasingly seek advanced, easy-to-use diagnostic tools that deliver immediate results, demand for such point-of-care solutions is expected to rise, contributing to broader market expansion. Additionally, the launch strengthens Zoetis' leadership position in veterinary diagnostics, encouraging further innovation and investment in the sector.
Global Companion Animal Diagnostics Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the companion animal diagnostics market report based on product, animal, testing category, end use, and region.
- Product Outlook (Revenue, USD Million, 2021 - 2033)
- Consumables, Reagents & Kits
- Equipment & Instruments
- Animal Outlook (Revenue, USD Million, 2021 - 2033)
- Dogs
- Cats
- Horses
- Other Companion Animals
- Testing Category Outlook (Revenue, USD Million, 2021 - 2033)
- Clinical Chemistry
- Microbiology
- Parasitology
- Histopathology
- Cytopathology
- Hematology
- Immunology & Serology
- Imaging
- Molecular Diagnostics
- Other Categories
- End Use Outlook (Revenue, USD Million, 2021 - 2033)
- Reference Laboratories
- Veterinary Hospitals and Clinics
- Home care settings
- Region Outlook (Revenue, USD Million, 2021 - 2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- Japan
- China
- India
- Australia
- Thailand
- South Korea
- Latin America
- Brazil
- Argentina
- Middle East & Africa
- South Africa
- UAE
- Saudi Arabia
- Kuwait
- Qatar
- Oman
Table of Contents
150 Pages
- Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.3. Estimates and Forecast Timeline
- 1.4. Research Methodology
- 1.5. Information Procurement
- 1.5.1. Purchased Database
- 1.5.2. GVR’s Internal Database
- 1.5.3. Secondary Sources
- 1.5.4. Primary Research
- 1.6. Information Analysis
- 1.6.1. Data Analysis Models
- 1.7. Market Formulation & Data Visualization
- 1.8. Model Details
- 1.8.1. Commodity Flow Analysis
- 1.9. List of Secondary Sources
- 1.10. Objectives
- Chapter 2. Executive Summary
- 2.1. Market Snapshot
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot
- Chapter 3. Anti-hypertensive Drugs Market Variables, Trends, & Scope
- 3.1. Market Lineage Outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.2. Market Restraint Analysis
- 3.3. Business Environment Analysis
- 3.3.1. Industry Analysis - Porter’s Five Forces Analysis
- 3.3.1.1. Supplier Power
- 3.3.1.2. Buyer Power
- 3.3.1.3. Substitution Threat
- 3.3.1.4. Threat of New Entrants
- 3.3.1.5. Competitive Rivalry
- 3.3.2. PESTLE Analysis
- Chapter 4. Anti-hypertensive Drugs Market: Product Business Analysis
- 4.1. Product Market Share, 2025 & 2033
- 4.2. Product Segment Dashboard
- 4.3. Market Size & Forecasts and Trend Analysis, by Product, 2021 to 2033 (USD Million)
- 4.4. ACE Inhibitors (ACEIs)
- 4.4.1. Market Size & Forecasts, 2021 - 2033 (USD Million)
- 4.5. Angiotensin II Receptor Blockers (ARBs)
- 4.5.1. Market Size & Forecasts, 2021 - 2033 (USD Million)
- 4.6. Direct Renin Inhibitor
- 4.6.1. Market Size & Forecasts, 2021 - 2033 (USD Million)
- 4.7. Calcium Channel Blockers
- 4.7.1. Market Size & Forecasts, 2021 - 2033 (USD Million)
- 4.8. Diuretics
- 4.8.1. Market Size & Forecasts, 2021 - 2033 (USD Million)
- 4.9. Mineralocorticoid Receptor Antagonists (MRAs)
- 4.9.1. Market Size & Forecasts, 2021 - 2033 (USD Million)
- 4.10. Beta-Blockers
- 4.10.1. Market Size & Forecasts, 2021 - 2033 (USD Million)
- 4.11. Alpha-1 Blockers
- 4.11.1. Market Size & Forecasts, 2021 - 2033 (USD Million)
- 4.12. Central Alpha-2 Agonists
- 4.12.1. Market Size & Forecasts, 2021 - 2033 (USD Million)
- 4.13. Direct Vasodilators
- 4.13.1. Market Size & Forecasts, 2021 - 2033 (USD Million)
- 4.14. Fixed-Dose Combinations (FDCs)
- 4.14.1. Market Size & Forecasts, 2021 - 2033 (USD Million)
- 4.15. Others
- 4.15.1. Market Size & Forecasts, 2021 - 2033 (USD Million)
- Chapter 5. Anti-hypertensive Drugs Market: Type Business Analysis
- 5.1. Type Market Share, 2025 & 2033
- 5.2. Type Segment Dashboard
- 5.3. Market Size & Forecasts and Trend Analysis, by Type, 2021 to 2033 (USD Million)
- 5.4. Standard Hypertension
- 5.4.1. Market Size & Forecasts, 2021 - 2033 (USD Million)
- 5.5. Treatment-Resistant Hypertension
- 5.5.1. Market Size & Forecasts, 2021 - 2033 (USD Million)
- 5.6. Hypertensive Emergency/Urgency
- 5.6.1. Market Size & Forecasts, 2021 - 2033 (USD Million)
- Chapter 6. Anti-hypertensive Drugs Market: Route of Administration Business Analysis
- 6.1. Route of Administration Market Share, 2025 & 2033
- 6.2. Route of Administration Segment Dashboard
- 6.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2021 to 2033 (USD Million)
- 6.4. Oral
- 6.4.1. Market Size & Forecasts, 2021 - 2033 (USD Million)
- 6.5. Transdermal
- 6.5.1. Market Size & Forecasts, 2021 - 2033 (USD Million)
- 6.6. Parenteral / Intravenous
- 6.6.1. Market Size & Forecasts, 2021 - 2033 (USD Million)
- Chapter 7. Anti-hypertensive Drugs Market: Distribution Channel Business Analysis
- 7.1. Distribution Channel Market Share, 2025 & 2033
- 7.2. Distribution Channel Segment Dashboard
- 7.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Million)
- 7.4. Retail Pharmacy
- 7.4.1. Market Size & Forecasts, 2021 - 2033 (USD Million)
- 7.5. Hospital Pharmacy
- 7.5.1. Market Size & Forecasts, 2021 - 2033 (USD Million)
- 7.6. Other
- 7.6.1. Market Size & Forecasts, 2021 - 2033 (USD Million)
- Chapter 8. Anti-hypertensive Drugs Market: Countries Estimates & Trend Analysis
- 8.1. Country Market Share Analysis, 2025 & 2033
- 8.2. Country Market Dashboard
- 8.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
- 8.3.1. U.S.
- 8.3.1.1. Key Country Dynamics
- 8.3.1.2. Target Disease Prevalence
- 8.3.1.3. Regulatory Framework
- 8.3.1.4. Reimbursement Framework
- 8.3.1.5. Anti-hypertensive Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.3.2. Canada
- 8.3.2.1. Key Country Dynamics
- 8.3.2.2. Target Disease Prevalence
- 8.3.2.3. Regulatory Framework
- 8.3.2.4. Reimbursement Framework
- 8.3.2.5. U.S. Anti-hypertensive Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.3.3. Mexico
- 8.3.3.1. Key Country Dynamics
- 8.3.3.2. Target Disease Prevalence
- 8.3.3.3. Regulatory Framework
- 8.3.3.4. Reimbursement Framework
- 8.3.3.5. Mexico Anti-hypertensive Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.4. Europe
- 8.4.1. Europe Anti-hypertensive Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.4.2. UK
- 8.4.2.1. Key Country Dynamics
- 8.4.2.2. Target Disease Prevalence
- 8.4.2.3. Regulatory Framework
- 8.4.2.4. Reimbursement Framework
- 8.4.2.5. UK Anti-hypertensive Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.4.3. Germany
- 8.4.3.1. Key Country Dynamics
- 8.4.3.2. Target Disease Prevalence
- 8.4.3.3. Regulatory Framework
- 8.4.3.4. Reimbursement Framework
- 8.4.3.5. Germany Anti-hypertensive Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.4.4. France
- 8.4.4.1. Key Country Dynamics
- 8.4.4.2. Target Disease Prevalence
- 8.4.4.3. Regulatory Framework
- 8.4.4.4. Reimbursement Framework
- 8.4.4.5. France Anti-hypertensive Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.4.5. Italy
- 8.4.5.1. Key Country Dynamics
- 8.4.5.2. Target Disease Prevalence
- 8.4.5.3. Regulatory Framework
- 8.4.5.4. Reimbursement Framework
- 8.4.5.5. Italy Anti-hypertensive Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.4.6. Spain
- 8.4.6.1. Key Country Dynamics
- 8.4.6.2. Target Disease Prevalence
- 8.4.6.3. Regulatory Framework
- 8.4.6.4. Reimbursement Framework
- 8.4.6.5. Spain Anti-hypertensive Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.4.7. Denmark
- 8.4.7.1. Key Country Dynamics
- 8.4.7.2. Target Disease Prevalence
- 8.4.7.3. Regulatory Framework
- 8.4.7.4. Reimbursement Framework
- 8.4.7.5. Denmark Anti-hypertensive Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.4.8. Sweden
- 8.4.8.1. Key Country Dynamics
- 8.4.8.2. Target Disease Prevalence
- 8.4.8.3. Regulatory Framework
- 8.4.8.4. Reimbursement Framework
- 8.4.8.5. Sweden Anti-hypertensive Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.4.9. Norway
- 8.4.9.1. Key Country Dynamics
- 8.4.9.2. Target Disease Prevalence
- 8.4.9.3. Regulatory Framework
- 8.4.9.4. Reimbursement Framework
- 8.4.9.5. Norway Anti-hypertensive Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5. Asia Pacific
- 8.5.1. Asia Pacific Anti-hypertensive Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.2. Japan
- 8.5.2.1. Key Country Dynamics
- 8.5.2.2. Target Disease Prevalence
- 8.5.2.3. Regulatory Framework
- 8.5.2.4. Reimbursement Framework
- 8.5.2.5. Japan Anti-hypertensive Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.3. China
- 8.5.3.1. Key Country Dynamics
- 8.5.3.2. Target Disease Prevalence
- 8.5.3.3. Regulatory Framework
- 8.5.3.4. Reimbursement Framework
- 8.5.3.5. China Anti-hypertensive Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.4. India
- 8.5.4.1. Key Country Dynamics
- 8.5.4.2. Target Disease Prevalence
- 8.5.4.3. Regulatory Framework
- 8.5.4.4. Reimbursement Framework
- 8.5.4.5. India Anti-hypertensive Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.5. Australia
- 8.5.5.1. Key Country Dynamics
- 8.5.5.2. Target Disease Prevalence
- 8.5.5.3. Regulatory Framework
- 8.5.5.4. Reimbursement Framework
- 8.5.5.5. Australia Anti-hypertensive Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.6. South Korea
- 8.5.6.1. Key Country Dynamics
- 8.5.6.2. Target Disease Prevalence
- 8.5.6.3. Regulatory Framework
- 8.5.6.4. Reimbursement Framework
- 8.5.6.5. South Korea Anti-hypertensive Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.7. Thailand
- 8.5.7.1. Key Country Dynamics
- 8.5.7.2. Target Disease Prevalence
- 8.5.7.3. Regulatory Framework
- 8.5.7.4. Reimbursement Framework
- 8.5.7.5. Thailand Anti-hypertensive Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.6. Latin America
- 8.6.1. Latin America Anti-hypertensive Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.6.2. Brazil
- 8.6.2.1. Key Country Dynamics
- 8.6.2.2. Target Disease Prevalence
- 8.6.2.3. Regulatory Framework
- 8.6.2.4. Reimbursement Framework
- 8.6.2.5. Japan Anti-hypertensive Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.6.3. Argentina
- 8.6.3.1. Key Country Dynamics
- 8.6.3.2. Target Disease Prevalence
- 8.6.3.3. Regulatory Framework
- 8.6.3.4. Reimbursement Framework
- 8.6.3.5. China Anti-hypertensive Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.7. Middle East and Africa
- 8.7.1. Middle East and Africa Anti-hypertensive Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.7.2. South Africa
- 8.7.2.1. Key Country Dynamics
- 8.7.2.2. Target Disease Prevalence
- 8.7.2.3. Regulatory Framework
- 8.7.2.4. Reimbursement Framework
- 8.7.2.5. South Africa Anti-hypertensive Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.7.3. Saudi Arabia
- 8.7.3.1. Key Country Dynamics
- 8.7.3.2. Target Disease Prevalence
- 8.7.3.3. Regulatory Framework
- 8.7.3.4. Reimbursement Framework
- 8.7.3.5. Saudi Arabia Anti-hypertensive Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.7.4. UAE
- 8.7.4.1. Key Country Dynamics
- 8.7.4.2. Target Disease Prevalence
- 8.7.4.3. Regulatory Framework
- 8.7.4.4. Reimbursement Framework
- 8.7.4.5. UAE Anti-hypertensive Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.7.5. Kuwait
- 8.7.5.1. Key Country Dynamics
- 8.7.5.2. Target Disease Prevalence
- 8.7.5.3. Regulatory Framework
- 8.7.5.4. Reimbursement Framework
- 8.7.5.5. Kuwait Anti-hypertensive Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- Chapter 9. Competitive Landscape
- 9.1. Participant Overview
- 9.2. Company Market Position Analysis
- 9.3. Company Categorization
- 9.4. Strategy Mapping
- 9.5. Company Profiles/Listing
- 9.5.1. Novartis
- 9.5.1.1. Overview
- 9.5.1.2. Financial Performance
- 9.5.1.3. Product Benchmarking
- 9.5.1.4. Strategic Initiatives
- 9.5.2. Sanofi
- 9.5.2.1. Overview
- 9.5.2.2. Financial Performance
- 9.5.2.3. Product Benchmarking
- 9.5.2.4. Strategic Initiatives
- 9.5.3. Bayer
- 9.5.3.1. Overview
- 9.5.3.2. Financial Performance
- 9.5.3.3. Product Benchmarking
- 9.5.3.4. Strategic Initiatives
- 9.5.4. Boehringer Ingelheim International GmbH
- 9.5.4.1. Overview
- 9.5.4.2. Financial Performance
- 9.5.4.3. Product Benchmarking
- 9.5.4.4. Strategic Initiatives
- 9.5.5. DAIICHI SANKYO COMPANY, LIMITED
- 9.5.5.1. Overview
- 9.5.5.2. Financial Performance
- 9.5.5.3. Product Benchmarking
- 9.5.5.4. Strategic Initiatives
- 9.5.6. Takeda Pharmaceutical Company Limited
- 9.5.6.1. Overview
- 9.5.6.2. Financial Performance
- 9.5.6.3. Product Benchmarking
- 9.5.6.4. Strategic Initiatives
- 9.5.7. Viatris Inc.
- 9.5.7.1. Overview
- 9.5.7.2. Financial Performance
- 9.5.7.3. Product Benchmarking
- 9.5.7.4. Strategic Initiatives
- 9.5.8. Teva Pharmaceutical Industries Ltd.
- 9.5.8.1. Overview
- 9.5.8.2. Financial Performance
- 9.5.8.3. Product Benchmarking
- 9.5.8.4. Strategic Initiatives
- 9.5.9. Sandoz (Novartis)
- 9.5.9.1. Overview
- 9.5.9.2. Financial Performance
- 9.5.9.3. Product Benchmarking
- 9.5.9.4. Strategic Initiatives
- 9.5.10. Sun Pharmaceutical Industries Ltd.
- 9.5.10.1. Overview
- 9.5.10.2. Financial Performance
- 9.5.10.3. Product Benchmarking
- 9.5.10.4. Strategic Initiatives
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
